Biosimilars: The Future of Biologic Therapy

Chronic diseases are continuing to rise globally, emphasizing the need for patients to have access to safe and effective treatments. Biologics represent a unique and powerful class of medications that have significantly changed how doctors manage conditions like cancer, diabetes, and autoimmune diseases. These treatments have led to outstanding patient outcomes—for example, biologics have halved the mortality rate for non-Hodgkin’s lymphoma. Presently, there are over 200 biologics and vaccines available worldwide, most of which are therapeutic proteins—lab-engineered proteins used in medicine, with insulin being the first developed. The field is expanding rapidly, with more than 900 biotechnology medicines and vaccines currently under development. Unlike traditional “small-molecule” drugs such as Aspirin, biologics are much more complex. They are derived from living organisms and cannot be produced solely through chemical synthesis. These drugs go by various terms including biologics, biologic therapies, biologic agents, BRMs (biological response modifiers), or immunotherapies. Biosimilars, also known as follow-on biologics or subsequent entry biologics, are highly similar versions of original biologic medicines that have lost their patent exclusivity. They offer more affordable treatment options and can stimulate competition in the biologic drug market. The original biologic is typically referred to as the reference, originator, or innovator product. A biosimilar must prove it has no clinically significant differences from its reference product in terms of safety, purity, and effectiveness. While they usually share the same primary structure and most molecular traits, slight variations in non-active components may occur.It’s important not to confuse biosimilars with generic drugs. Generics are exact chemical copies of brand-name drugs, identical in active ingredients, dosage, strength, route of administration, and performance—they are “bioequivalent.” Biosimilars, on the other hand, are “highly similar,” not identical, due to being made from living cells—this distinction is crucial. Modern biologic drugs have shown they can significantly improve patient health, but access remains limited—mainly due to high costs. As many well-known biologics are approaching the end of their patent and exclusivity periods, biosimilars are becoming a promising alternative. These treatments are especially appealing because they are generally more affordable, which can enhance access and offer broader benefits to patients, healthcare providers, and the healthcare system as a whole.